相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The STIMULATE-ICP phase 3 cluster-randomized trial enrolled 1,152 Long COVID patients across 114 NHS primary care networks, finding a 12.6% reduction in fatigue scores with specialist integrated care. - Multi-organ MRI (Coverscan) offered no incremental improvement in fatigue or quality of life at 12 or 24 weeks compared with usual specialist care alone. - Digital rehabilitation via the Living With COVID Recovery app showed a small, statistically significant improvement in fatigue at 24 weeks (−1.14 points on FAS, P=0.023), but the clinical significance remains uncertain. - The trial demonstrates the feasibility of pragmatic cluster-randomized designs for evaluating complex care pathways in post-infectious conditions, though unblinded interventions and heterogeneous protocols present inherent methodological limitations.
- The UK has agreed to freeze existing pharmaceutical intellectual property protections, including 10-year RDP and 5-year SPC terms, as part of a new trade deal with Switzerland. - This marks the first time the UK has explicitly written drug patent rules into a trade agreement, preventing either country from shortening exclusivity periods without breaching terms. - Health campaigners warn the deal entrenches a system that could increase NHS medicines costs and limits future governments' ability to regulate in the public interest. - The pharmaceutical industry welcomed the move, with ABPI and AstraZeneca executives stating it provides stability to drive investment in research and clinical trials.
- The UK government has six months to decide whether to terminate its NHS contract with Palantir, worth up to $440 million, via a break clause next February. - Greater Manchester is the sole English region refusing to adopt Palantir's federated data platform, claiming its homegrown ADSP is functionally superior and more trusted. - Parliamentary reports warn that dependence on Palantir represents an "unacceptable point of weakness," while Palantir cites benefits including 110,000 additional operations and 800,000 patients removed from waiting lists. - Protests and a government review of "every single aspect" of the contract underscore tensions over data privacy, national security, and the company's political affiliations.
- UK biotech sector raised £552 million in total equity financing during Q1 2026, marking an 18% increase from the previous quarter's £466 million. - Venture capital investment rose 17% to £516 million with deal activity surging 67% year-on-year to 25 transactions, indicating broader distribution of funding across companies. - Major M&A deals including Eli Lilly's £4.6 billion acquisition of Centessa Pharmaceuticals and Amgen's £626 million purchase of Dark Blue Therapeutics reinforced international interest in UK biotech assets. - The UK captured 57% of all European biotech venture capital in Q1 2026, though public market activity remained stagnant with no British companies going public during the quarter.
- Virax Biolabs completed recruitment for its first UK clinical study (VRX-002) ahead of schedule, enrolling 160 participants across Long COVID, post-treatment Lyme disease, and ME/CFS cohorts with initial data expected in Q2 2026. - The company established a clinical collaboration with Emory University's ADJUST Center to support U.S. regulatory plans for its ViraxImmune™ T cell assay in post-acute sequelae of COVID-19. - Mechanistic data presented at WIRM showed progressive up-regulation of T cell exhaustion markers in PAIS patients, supporting the rationale for ViraxImmune™ diagnostic technology. - The company maintains a debt-free balance sheet with $3.3 million in cash while expanding its ImmuneSelect research-use-only portfolio as a potential near-term revenue driver.
- Merck announced it is halting all research operations in the U.K. and abandoning plans for a major London research center in protest of the country's drug pricing policies. - The pharmaceutical industry has grown increasingly frustrated with the U.K. government's failure to support innovation and pay warranted prices for new medicines through NHS procurement processes. - This follows a broader trend of pharmaceutical companies withdrawing investments from the U.K., with AstraZeneca earlier pulling out of a vaccine manufacturing center near Liverpool due to reduced government subsidies. - The decision represents a significant blow to the U.K.'s efforts to promote life sciences investment despite its renowned academic institutions and National Health Service infrastructure.
- Cyted Health raised $44 million in Series B funding led by EQT Life Sciences to accelerate commercial expansion of its gastrointestinal molecular diagnostics platform in the United States. - The company's EndoSign device, FDA 510(k)-cleared for minimally invasive esophageal cell collection, has completed over 35,000 tests across the UK's National Health Service with demonstrated clinical impact. - Cyted launched the DETECT-ME clinical validation study across 18 US sites to build evidence for its platform's efficacy in the North American market. - Esophageal cancer remains one of the deadliest cancers globally with survival rates between 20-25%, highlighting the critical need for earlier detection technologies.
- The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland. - Over 1,000 postmenopausal women in Scotland are expected to benefit from this anabolic therapy, which promotes new bone formation through daily injections for up to 18 months. - Hip fractures cost the NHS £2 billion annually, with total osteoporotic fracture costs exceeding £4.6 billion and projected to reach £6 billion by 2030. - The approval follows NICE's previous recommendation in August 2024 for England, Wales, and Northern Ireland, ensuring equitable access across the UK.
- Russia's Gamaleya Center plans to begin treating cancer patients with its personalized mRNA vaccine by September-October 2025, following regulatory approval expected this summer. - The vaccine uses AI-driven algorithms to create individualized mRNA blueprints based on patient genetic data, reducing development time from months to hours. - Pre-clinical trials demonstrated significant tumor suppression and prevention of metastases, with the vaccine designed to target over 300 histological and phenotypic cancer types. - The treatment will be provided free of charge to patients, representing a unique commitment to accessible cancer immunotherapy.
- Italy leads 5EU markets with the highest number of HTA decisions in Q1 2025, accounting for 27% of all assessments, with 82% positive outcomes compared to 95% in 2024. - France demonstrates a notable shift in HTA approach with a 55% reduction in negative decisions in Q1 2025, moving away from its historically conservative stance that yielded no positive decisions in Q1 2024. - Price changes for innovative medicines increased by 19.8% across 5EU in Q1 2025, with France and Germany accounting for 91% of all price adjustments, showing average price declines of 10% in both markets.
